Microfluidic systems redefined biology by providing platforms that handle small fluid volumes, catalyzing advancements in cellular and molecular studies.

Beyond The Scientist’s coverage of COVID-19’s molecular underpinnings were many other stories highlighting the advances made in scientists’ understanding of the biology of cells.

Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.

Using a circuit-based system, scientists determined the ideal transcription factor levels to promote the successful reprogramming of fibroblasts into induced pluripotent stem cells.

Douglas Blackiston’s frog-fueled research seeks to push the boundaries of understanding developing organisms.

Associate Professor, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder. Age: 43

Innovative instruments, often jerry-built from parts of other devices, are making a wide array of new projects possible One look through something called a confocal microscope was all it took for William Sunderland to make a drastic change in his career plans. A math student with what appeared to be a bright future in computers, he peeked one day through the lens of a microscope invented in the lab where he worked. The dazzlingly detailed pictures of living cells convinced him to switch his ma

But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy

But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy